USX:PKI - Perkinelmer, Inc. (USD 78.34) Perkinelmer, Inc.
Sector: Health Technology, Industry: Medical Specialties
Add to Watchlist

Yahoo Finance

USD 78.34    +0.460 (+0.59%)
Show Basic Chart | 3M    6M    1Y    3Y    5Y          

9 Apr 2020


9 Apr 2020

Day Change: 0.460 (0.59%)

52 Wk Range: 62.91 - 102.455

Day's Range: 77.215 - 79.575

Last Volume: 701,165

Current Yield: 0.36%

Projected Yield: 0.36%

Open: USD 78.43

9 Apr 2020

Metric PKI S.Median
Beta 0.91 0.84
VaR 17.43 25.23
E.Shortfall 25.15 45.03
Liquidity 771.76K 95.2K


9 Apr 2020

PE: 38.154

Market Cap: 8.7B

Price Over Book: 3.086

Price Over Sales: 3.01

Return On Assets: 3.5%

Return On Equity: 8.1%

Price Over NAV: [Friends Only]


CEO: Robert F. Friel

Headquarters: Boston

Employees: 8,000

Sector: Health Technology

Industry: Medical Specialties

Useful Links


PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates through two segments, Discovery and Analytical Solutions and Diagnostics. The Discovery and Analytical Solutions segment develops and provides analytical technologies, solutions, and services that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. It also provides solutions to farmers and food producers; an analytical instrumentation for the industrial market, which includes the chemical, electronics, energy, food, lubricant, petrochemical, and polymer industries; and laboratory services. This segment's offers a suite of solutions, including reagents, liquid handling systems, and detection and imaging technologies that enable scientists to enhance life sciences research and drug discovery processes. Its research portfolio includes a range of systems consisting of imaging, detection, and extraction instrumentation for use on in vitro, ex vivo, and in vivo models, analysis hardware, and software; and a range of consumable products, including drug discovery and research reagents. The Diagnostics segment provides early detection for genetic disorders from pregnancy to early childhood, as well as flat panel X-ray detectors and infectious disease testing for the diagnostics market. This segment also develops technologies that enable and support sample-to-sequencer workflow using next-generation DNA sequencing for applications in oncology, genetic testing, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1931 and is headquartered in Waltham, Massachusetts.